(PharmaNewsWire.Com, December 17, 2019 ) Market Overview The global anti-hypertension drugs market is estimated to be USD 33.12 billion in 2017, and the market has grown at a CAGR of YY% in the period 2013-2017.
The global anti-hypertension therapeutics market is estimated to decline at a CAGR of YY% during 2017-2020 and grow after that. Patent expiry of the major drugs is the primary reason for the decline in the market during 2017-2020 while new launches are forecasted to increase the demand from 2020-2025.
Market Dynamics High penetration of fixed dosage drugs, a rise in prevalence of the global population suffering from hypertension, growth in the chronic diseases, and growing patient assistance programs are some of the major factors driving the growth of the market.
Patent expiry of major drugs, the adverse impact of drugs, the presence of a considerable number of substitutes, and poor patient compliance are the significant factors challenging the growth of the market in the forecasted period.
Market Segmentation By Drug Type Anti Hypertension market by drug type is segmented into Systemic Hypertension and Pulmonary Arterial Hypertension. Systemic Hypertension market accounts for the largest market share in the forecasted period while the market is witnessing negative growth in the market in the predicted period. Patent expiry of drugs and generic erosion are the major factors for the decline in the market value of the Systemic Hypertension market.
Pfizer’s Micardis and Daiichi Sankyo’s Benicar are some of the major drugs whose patents have been expired during 2014-2017. The Pulmonary Arterial Hypertension market accounts only for a significant market share in the forecasted period while the market between 3.5%-5.5% annually during the forested period 2018-2025. Expiry of Actelion Pharmaceuticals Tracleer in 2015 harmed the growth of the market while the growing usage of fixed-dose combinations is estimated to drive the growth of the market.
By Geography In 2017, North America dominated the global anti-hypertension therapeutics market with the United States being the major contributor to the North American and global markets.
The market in the North American region has been continuously declining due to the patent expiry while companies focus on combination therapy has prevented the growth of the market share.
Expected new product launches in the forecasted period are estimated to further support the growth of the market in the predicted period.
The Asia-Pacific region is the fastest-growing market in the forecasted period due to increasing awareness, large patient population, rising per capita health care spending, and government initiatives.
Competitive Trends The majority of the focus by companies in the anti-hypertension therapeutics market is focusing on the development of generic drugs with very few products in the pipeline for the novel drugs. Novartis, Sanofi, Actelion Pharmaceuticals, AstraZeneca, Boehringer Ingelheim, and Daiichi Sankyo are some of the major companies in the global anti-hypertension therapeutics market.
About Us: DataM Intelligence was established on an elemental idea of publishing Advanced Market Research Reports with precise data points & utmost accuracy that will accelerate the decision-making in designing disruptive solutions. We monitor and analyze the market by dissecting various parameters such as market influencers, competitive intensity, innovations, trends, and emerging products.
For more information: Sai Kiran Sales Manager Website: www.datamintelligence.com Email: info@datamintelligence.com
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
